Intuitive Surgical stock trades near record levels as da Vinci procedures grow

Intuitive Surgical stock continues to be supported by rising demand for robotic-assisted surgery, with the US-based medical technology group Intuitive Surgical Inc. (ISIN US46120E6023) benefiting from growing procedure volumes and a larger installed base of its da Vinci systems. As of 31 December 2024, the company reported a market capitalization in the tens of billions of dollars and shares trading close to prior record highs, underpinned by double-digit revenue growth and robust cash generation according to its investor presentations.

Revenue up double digits

According to the company’s most recent annual reporting for fiscal 2024, Intuitive Surgical generated total revenue of roughly $7 billion, an increase of around 13% compared with fiscal 2023, reflecting higher procedure volumes and expansion of its installed base of da Vinci surgical systems. In that reporting, management noted that recurring revenue from instruments, accessories, and services represented a majority of total sales, indicating a business mix that is less dependent on one-time system placements and more on ongoing utilization.

In the same fiscal 2024 period, Intuitive Surgical’s net income was approximately $2 billion, up from about $1.7 billion in fiscal 2023, corresponding to earnings growth in the mid-teens percentage range. The company’s operating margin also improved by several percentage points year on year, driven by scale effects as procedure volumes grew and the installed base matured. This margin expansion, combined with strong free cash flow generation in excess of $1.5 billion in fiscal 2024, has strengthened the balance sheet and supports continued investment in research and development and geographic expansion.

Procedure growth supports Intuitive Surgical stock

A key driver for Intuitive Surgical stock is the ongoing growth in da Vinci procedure volumes, which the company reported as rising more than 20% year on year in 2024. Minimally invasive robotic procedures across general surgery, gynecology, urology, and thoracic surgery are increasingly being adopted by hospitals seeking to improve patient outcomes and operating room efficiency. The company’s installed base of da Vinci systems exceeded 8,000 units worldwide by the end of 2024, up from around 7,000 a year earlier, giving Intuitive Surgical a broad footprint across North America, Europe, and Asia.

Intuitive Surgical’s recurring revenue stream from instruments and accessories, which are used in every procedure, grew at a rate slightly above overall revenue growth in fiscal 2024. This reflects increased utilization of existing systems and broader adoption of robotic-assisted surgery in established hospitals. Service revenue, which includes maintenance and upgrades of installed systems, also expanded at a double-digit pace over the same period. For investors, this revenue mix provides visibility into future cash flows, as hospitals typically commit to multi-year service contracts once a da Vinci system is installed.

da Vinci systems drive segment revenues

The da Vinci surgical system is Intuitive Surgical’s flagship product, forming the backbone of its revenue structure. The company reported that system placements accounted for roughly one quarter of total revenue in fiscal 2024, with instruments, accessories, and services making up the remaining three quarters. System placement growth in 2024 was in the high single digits percentage range, a slower pace than procedure growth, signaling that utilization of existing systems is a central driver of earnings leverage.

By clinical area, general surgery and gynecology procedures together represented more than 60% of da Vinci procedure volume in 2024, according to company data. Urology and thoracic procedures contributed additional meaningful shares, and newer indications such as colorectal and bariatric surgery expanded faster than the average, albeit from smaller bases. Intuitive Surgical has also highlighted growing adoption in markets outside the United States, with international procedures representing more than 30% of total volume in 2024, up several percentage points compared with fiscal 2023.

Intuitive Surgical stock and market valuation

Intuitive Surgical stock is listed on Nasdaq under the ticker ISRG, and the company is a member of the S&P 500 index. As of late 2024, shares traded at a level corresponding to a forward price-to-earnings multiple significantly above the broader market, reflecting investor expectations for continued double-digit growth in procedures and earnings. The market capitalization at that time was around $120 billion, compared with approximately $100 billion a year earlier, highlighting the degree to which valuation has expanded alongside fundamentals.

From a balance sheet perspective, Intuitive Surgical reported substantial cash and short-term investments and no material long-term debt at the end of fiscal 2024. This financial position gives the company flexibility to fund its research and development pipeline, invest in new training centers, and support strategic partnerships with hospitals. Capital expenditures in 2024 were on the order of hundreds of millions of dollars, focused on manufacturing capacity and technology upgrades, while returning capital to shareholders mainly through minimal dilution rather than large-scale share repurchase or dividends.